Skip to main content
Signal8

VOLITIONRX LTD (VNRX)

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Sector: In Vitro & In Vivo Diagnostic Substances

Industry: Medical - Devices

VolitionRX Ltd logo

VolitionRX Ltd

NYSE:VNRXHealthcare
Pre-4.32%$0.1770
Close$0.1850+3.58%AH$0.1700+4.12%since
Mkt Cap$5.56M
Float29.57M
O/S30.06M
Inst Own6.7%
SI3.9%
Dilution
VolitionRX Ltd logoNYSE:VNRXPre$0.1770-4.32%
FormDescription
8-K
Current Report
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
3.02
2
13D/A
Beneficial Ownership Report (Active, Amended)
8-K
3.02
2
8-K
8.01,9.01
3
EFFECT
Notice of Effectiveness
1
S-3/A
S-3/A
13D
8-K
8-K
3.02
2
S-3
8-K
3.02
3
S-8
SEC Filing
3
13G/A
Beneficial Ownership Report (Amended)
10-Q
8-K
8-K
3.02
3
8-K
5.03,5.07,9.01
EFFECT
Notice of Effectiveness
S-3
8-K
3.02
1

1-25 of 1,152

…